Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 143 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... May 3, 2023 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 2026 ESMO Breast Cancer Award Recipient Announced March 31, 2026 Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... January 9, 2026 Load more HOT NEWS Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent...
